The 36-month beta value for PYXS is also noteworthy at 1.34. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PYXS is 44.07M, and at present, short sellers hold a 13.29% of that float. The average trading volume of PYXS on November 15, 2024 was 525.13K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PYXS) stock’s latest price update
Pyxis Oncology Inc (NASDAQ: PYXS)’s stock price has dropped by 0.00 in relation to previous closing price of 4.28. Nevertheless, the company has seen a gain of 8.63% in its stock price over the last five trading days. benzinga.com reported 2024-11-08 that Stephens has initiated coverage on Pyxis Oncology Inc PYXS, highlighting the company’s technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, stability, and tolerability.
PYXS’s Market Performance
Pyxis Oncology Inc (PYXS) has seen a 8.63% rise in stock performance for the week, with a 29.70% gain in the past month and a 27.38% surge in the past quarter. The volatility ratio for the week is 11.20%, and the volatility levels for the past 30 days are at 8.22% for PYXS. The simple moving average for the last 20 days is 8.78% for PYXS’s stock, with a simple moving average of 5.59% for the last 200 days.
Analysts’ Opinion of PYXS
Many brokerage firms have already submitted their reports for PYXS stocks, with Stephens repeating the rating for PYXS by listing it as a “Overweight.” The predicted price for PYXS in the upcoming period, according to Stephens is $13 based on the research report published on November 08, 2024 of the current year 2024.
Stifel, on the other hand, stated in their research note that they expect to see PYXS reach a price target of $10. The rating they have provided for PYXS stocks is “Buy” according to the report published on August 08th, 2024.
Jefferies gave a rating of “Buy” to PYXS, setting the target price at $10 in the report published on May 07th of the current year.
PYXS Trading at 16.41% from the 50-Day Moving Average
After a stumble in the market that brought PYXS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.52% of loss for the given period.
Volatility was left at 8.22%, however, over the last 30 days, the volatility rate increased by 11.20%, as shares surge +32.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.29% upper at present.
During the last 5 trading sessions, PYXS rose by +8.63%, which changed the moving average for the period of 200-days by +12.34% in comparison to the 20-day moving average, which settled at $3.93. In addition, Pyxis Oncology Inc saw 137.78% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for PYXS
Current profitability levels for the company are sitting at:
- -3.43 for the present operating margin
- 0.85 for the gross margin
The net margin for Pyxis Oncology Inc stands at -2.93. The total capital return value is set at -0.38. Equity return is now at value -39.34, with -30.03 for asset returns.
Based on Pyxis Oncology Inc (PYXS), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -2.61. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -39.25.
Currently, EBITDA for the company is -78.49 million with net debt to EBITDA at -0.13. When we switch over and look at the enterprise to sales, we see a ratio of 13.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.33.
Conclusion
In summary, Pyxis Oncology Inc (PYXS) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
